5210results about "Glycosylases" patented technology

Embodiments of the present disclosure provide insulin formulations having a near neutral pH and improved pharmacokinetic / pharmacodynamic properties, and uses in insulin infusion devices that may provide extended infusion period up to 7-14 days. Also provided are systems for administering insulin, the system may include a first reservoir, a second reservoir, an insulin pump configured to administer contents of the first reservoir or the second reservoir, and one or more hardware processors in communication with the insulin pump.

Methods and compositions to minimize barcode exchange during the preparation of barcoded next-generation sequencing libraries prepared from a single cell. The methods utilize oligonucleotides containing a 3′-terminated blocking group or sequences that prevent amplification or extension.

An automatic dishwashing detergent water-soluble pouch includes a water-soluble film that forms at least two separate chambers that are enclosed by water-soluble film. The separate chambers are: a first chamber; and a second chamber. The first chamber is connected to the second chamber by a linking portion of water-soluble film, the length of the linking portion of water-soluble film between the first chamber and second chamber is at least 0.5 cm, the first chamber and second chamber include detergent ingredients, and the second chamber includes an amylase.

The invention belongs to the technical field of gene engineering, and particularly relates to mutants of murA and ygeA genes and application of the mutants in production of human milk oligosaccharides. According to the invention, murA and ygeA genes of escherichia coli are edited by using a gene editing technology, so that a genetic engineering chassis strain carrying murA and ygeA mutants is obtained. Further, the chassis strain is applied to the construction process of production strains of LNT II, LNnT, LNT, 3 '-SL and 6'-SL, and the yield of the LNT II, the LNnT, the LNT, the 3 '-SL and the 6'-SL is further increased.

The invention belongs to the technical field of gene engineering, and particularly relates to a beta-glycosidase SS-BGL mutant for preparing rare ginsenosides and application of the beta-glycosidase SS-BGL mutant. The beta-glycosidase SS-BGL mutant is obtained by conducting single-site mutation or double-site mutation on beta-glycosidase SS-BGL with the amino acid sequence shown as SEQ ID NO.1. The beta-glycosidase SS-BGL mutant is obtained by conducting single-site mutation or double-site mutation on beta-glycosidase SS-BGL with the amino acid sequence shown as SEQ ID NO.2. Wherein the single site mutation is that phenylalanine at the 229 site of SEQ ID NO. 1 is mutated into proline; the double-site mutation is as follows: phenylalanine at the 229 site in SEQ ID NO. 1 is mutated into proline, and glycine at the 301 site is mutated into proline; or the phenylalanine at the 229 site in SEQ ID NO. 1 is mutated into proline, and the leucine at the 337 site is mutated into valine; or the phenylalanine at the 229 site in SEQ ID NO. 1 is mutated into the proline, and the glycine at the 338 site is mutated into the proline. On the basis of natural beta-glycosidase SS-BGL, the molecular structure of the beta-glycosidase SS-BGL is modified through site-directed mutagenesis, and four beta-glycosidase SS-BGL mutants with the saponin conversion activity improved are obtained.

According to the invention, there is provided a which composition is in the form of an amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of at least one biopharmaceutical drug compound; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. maltodextrins). Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Powder compositions may be produced by spray-drying the various components together in combination.

The invention relates to the technical field of microbial fermentation, and discloses a genetically engineered bacterium of high-yield D-pantothenic acid as well as a preparation method and application of the genetically engineered bacterium. The D-PA yield of the engineering bacteria is greatly improved through the following effects that acetolactate synthase IlvB and IlvN shunted by pyruvic acid are subjected to overexpression, meanwhile, a transcription attenuation region is deleted, and valine feedback inhibition sites are mutated; the method comprises the following steps: overexpressing keto-alcohol acid reductoisomerase IlvC and dihydroxy acid dehydratase IlvD, and converting the IlvC coenzyme preference from NADPH into NADH, so as to break through the upstream of D-PA synthesis; overexpression of PanB is carried out, overexpression of a serine-glycine transport system is carried out, and synthesis of 5, 10-methylenetetrahydrofolic acid is promoted; meanwhile, the expression of ketopantoic acid reductase PanE is enhanced; and finally, over-expressing pantothenic acid synthetase PanC, and increasing the content of a cofactor ATP required by the PanC. According to the engineering bacteria provided by the invention, through overall reinforcement of the multiple modules, cell growth is improved due to balance of cofactors and increase of D-PA, and the yield of D-PA reaches an unprecedented height.

The present disclosure provides proteins useful for preventing, treating, inhibiting and / or eliminating infestation and infection of plants caused by various phytopathogenic pests, as well as formulations comprising such proteins, polynucleotides encoding such proteins, organisms expressing such proteins, and methods for preparing such proteins. And methods of using such proteins, formulations, polynucleotides, and organisms in agricultural and other effort areas.

The present disclosure provides, in various embodiments, stable injectable particle suspensions of therapeutic biologics and hyaluronan degrading agents that permit administration without the need for resuspension. In particular, the compositions disclosed herein are highly concentrated, low-volume injectable particle suspensions that increase bioavailability of therapeutic biologics.

The present invention relates to methods of treatment of light chain amyloidosis and other CD38-positive hematological malignancies with anti-CD38 antibodies.

The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.

The invention discloses a compound enzyme preparation for improving the absorption and utilization rate of a fertilizer and a preparation method thereof, and belongs to the technical field of enzyme preparations. The compound enzyme preparation is prepared from the following components in parts by weight: 100 parts of purified water, 6 to 8 parts of modified cellulase, 10 to 12 parts of immobilized protease, 10 to 12 parts of phosphatase, 10 to 14 parts of urease, 8 to 10 parts of nitrate reductase, 10 to 12 parts of pectinase, 8 to 10 parts of chitinase, 6 to 8 parts of xylanase, 10 to 12 parts of beta-glucosidase, 10 to 12 parts of superoxide dismutase and 4.5 to 6 parts of a microbial agent, the modified cellulase is obtained by chemically modifying cellulase; the immobilized protease is prepared by the following steps: adsorbing activated and coupled modified polylactic acid and a protease solution, crosslinking with glutaraldehyde, filtering, washing and drying. The compound enzyme preparation improves the fertilizer absorption and utilization rate of plants.

The invention discloses recombinant escherichia coli for producing D-psicose and a preparation method of the recombinant escherichia coli, and belongs to the field of genetic engineering. The technical problem to be solved in the invention is how to supply microorganisms for growth by using glycerol, acetic acid, fatty acid and the like as raw materials and prepare D-psicose by using glucose as a raw material. The invention provides recombinant Escherichia coli, which uses glycerol, acetic acid, fatty acid and the like as carbon sources to amplify (grow) the recombinant Escherichia coli, and uses D-glucose as a substrate to prepare D-psicose. According to the recombinant escherichia coli provided by the invention, glycerol, acetic acid, fatty acid and the like can be used as carbon sources for microbial growth, and D-psicose is synthesized by taking D-glucose as a raw material after the microbial growth reaches a certain biomass. Furthermore, a corresponding technical route for synthesizing the D-psicose is established.

The invention provides bacillus paralicheniformis NJ102 and application thereof, and belongs to the technical field of microorganisms. The bacillus paralicheniformis NJ102 disclosed by the invention has the capabilities of resisting low temperature and saline and alkaline, and can endure the low temperature of 10 DEG C, the salt stress with the salt content of 17% and the strong alkali stress with the pH value of 12.5. Meanwhile, the bactericidal composition has a relatively good inhibition effect on ralstonia solanacearum, rhizoctonia solanacearum and phytophthora capsici, and can effectively prevent and treat tomato bacterial wilt, root rot and fruit rot. The bacillus paralicheniformis disclosed by the invention also has relatively strong capability of producing protease, cellulase, amylase and IAA (Indoleacetic Acid), has a relatively good growth promoting effect on tomatoes, and has great application potential in the aspect of biopesticide.

The invention relates to a gene modified cell and a method for producing fucosyllactose by using the gene modified cell, in particular to a kluyveromyces kluyveromyces gene modified cell and application thereof, and belongs to the technical field of biological gene engineering. The present invention provides a genetically modified cell comprising a recombinant nucleic acid sequence encoding a polypeptide having an [alpha]-1, 2-fucosyltransferase polypeptide ([alpha]-1, 2-fucosyltransferase) activity. The alpha-1, 2-fucosyltransferase polypeptide includes, but is not limited to, polypeptides having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical amino acid sequences with the amino acid sequences of SEQ ID NO: 1-25. According to the gene modified cell, the fucosyllactose synthesis capability of an original strain is improved.

The disclosure relates to compositions and methods for altering, e.g., enhancing, the expression of GCase proteins, whether in vitro and / or in vivo. Such compositions include delivery of an adeno-associated viral (AAV) particle. The compositions and methods of the present disclosure are useful in the treatment of subjects diagnosed with, or suspected of having Parkinson Disease or related condition resulting from a deficiency in the quantity and / or function of GBA gene product or associated with decreased expression or protein levels of GCase protein.

The invention provides a Kitasatospora xanthophycea JY01 strain and application thereof, the strain is separated from intestinal tracts of spring silkworms, has good disease-resistant and growth-promoting effects, and is specifically expressed in that cellulase, beta-1, 3-glucanase, siderophore and auxin IAA can be secreted; pot experiments show that the biocontrol efficiency of the microbial inoculum to wheat stalk rot is 57.90%, the biocontrol efficiency of the microbial inoculum to corn stalk rot is 46.41%, and the plant height and fresh weight are both significantly increased. The microbial agent is expected to be applied to preparation of biological bacterial fertilizer for effectively preventing and controlling soil-borne fungal diseases.

The invention relates to the technical field of biology, in particular to random type difunctional carrageenase and application. The invention provides a random type difunctional carrageenase, the amino acid sequence of which is SEQ ID NO.1. The random type difunctional carrageenase can degrade iota-carrageenan and kappa-carrageenan in a random type internally tangent action mode to generate oligosaccharides with different polymerization degrees, is beneficial to research on the structure-function relationship of the carrageenan and the oligosaccharides thereof, and can be applied to the fields of food industry, chemical analysis and the like. The random type difunctional carrageenase can be applied to preparation of iota-carrageenan with different molecular weights and a series of oligosaccharides.

The invention relates to bacillus velezensis for producing alpha-amylase from a tobacco source and application of the bacillus velezensis, and belongs to the technical field of microorganisms. The bacillus velezensis for producing the alpha-amylase from the tobacco source is A8-1, and the preservation number of the bacillus velezensis is CCTCC (China Center For Type Culture Collection) NO: M 20232632. The activity of the alpha-amylase produced by the bacillus velezensis A8-1 can reach up to 147.85 + / -0.05 U / mL at the high temperature of 70 DEG C through determination, and the content of tobacco starch in tobacco products can be effectively reduced when the alpha-amylase is applied to the tobacco products, so that the quality of the tobacco products is improved. On one hand, the quality, applicability and utilization rate of low-grade and low-grade tobacco leaves can be improved; on the other hand, the quality grade of tobacco leaves can be improved, and defects of high-quality tobacco leaves are overcome. Meanwhile, valuable microbial resources are provided for the tobacco industry, and a new technology is provided for promoting high-quality development of tobacco industry enterprises.

The disclosure relates to compositions and methods for, inter alia, altering, e.g., enhancing, the level of GBA1 protein via delivery using an adeno-associated viral (AAV) capsid variant. The compositions and methods of the present disclosure are useful, inter alia, for the treatment of subjects who have, have been diagnosed with having, or are at risk of having a GBA1-related disorder, e.g., Parkinson's Disease (PD), Gaucher Disease (GD), Dementia with Lewy Bodies (DLB), or Lewy Body Dementia (LBD).

Provided herein are methods of treating bullous pemphigoid using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. FcRn antagonists for use in the treatment of bullous pemphigoid and for use in the manufacture of a medicament for the treatment of bullous pemphigoid are also provided herein.

The present disclosure provides, in various embodiments, stable injectable particle suspensions of therapeutic biologics and hyaluronan degrading agents that permit administration without the need for resuspension. In particular, the compositions disclosed herein are highly concentrated, low-volume injectable particle suspensions that increase bioavailability of therapeutic biologics.

The present disclosure relates to a process for preparing an upcycled material from a dry raw material with a moisture content of 0-30% w / w comprising lignocellulose and derived from spent cereal and / or pseudocereal grain and / or food waste or lignocellulosic biomass or a mixture thereof, the process comprising: a) a pre-treatment comprising the steps of: i) grinding and / or pulverizing the raw material to obtain a powder capable of passing through a sieve having a mesh size of 10-1000 μm and ii) performing autohydrolysis, followed by b) enzymatic hydrolysis of the of powder obtained from step ii), wherein the enzymatic hydrolysis comprises adding an enzyme mixture comprising at least a glucanase and a xylanase, and c) a post-treatment comprising the step of grinding and / or pulverizing the enzymatically hydrolysed mixture obtained from step b) to obtain the upcycled material in the form of a flour-like product.

Methods for stimulating plant growth and / or promoting plant health using free enzymes or recombinant microorganisms that overexpress enzymes are provided. Plant seeds coated with free enzymes or recombinant microorganisms that overexpress enzymes are also provided. Compositions comprising a fertilizer and an enzyme or a recombinant microorganism that overexpresses an enzyme are provided. Modified enzymes having ACC deaminase activity, recombinant microorganisms expressing the modified enzymes, plant seeds treated with the modified enzymes or recombinant microorganisms, and methods for stimulating plant growth and / or promoting plant health using the modified enzymes or recombinant microorganisms are also provided.

The present invention relates to a multi-chambered automatic dishwashing detergent watersoluble pouch. The pouch of the present invention enables amylase enzyme activity to be specifically targeted to the pre-wash stage of an automatic dishwashing cycle as well as the main-wash stage of an automatic dishwashing cycle.

The invention disclosed concerns a fixed dose combination (FDC) of pertuzumab, trastuzumab, and, optionally, recombinant human hyaluronidase (rHuPH20), which is administered subcutaneously to patients. The final efficacy and safety data for the FeDeriCa clinical trial, United States Prescribing Information (USPI) (including home-use) methods, and primary analysis of the PHranceSCa clinical trial are disclosed and claimed.

Methods for enzymatic modification of saponin produced by plant cell culture, products prepared thereby, uses of the products, and other related aspects, are disclosed. The saponin can be obtained from a plant cell culture extract of the species of the Quillaja, such as an extract of the Quillaja saponica Molina. The invention further relates to a method for preparing the saponin from the extract of the Quillaja saponica Molina.

The invention relates to the technical field of isoflavone biotransformation, in particular to a soybean isoflavone aglycone preparation method based on enzymolysis. Comprising the following steps: inoculating Kluyveromyces marxianus into a basic culture medium for shake cultivation; after culturing, centrifuging, washing and resuspending to obtain a bacterial suspension as a leavening agent, and inoculating the bacterial suspension to a bean dreg composite culture medium for shaking table fermentation for 48-96 hours; centrifuging the fermentation liquor at 0-4 DEG C, and collecting supernate to obtain crude beta-glucosidase; the crude enzyme liquid is sequentially subjected to ammonium sulfate salting-out, ion exchange chromatography and twice sephadex chromatography, and purified beta-glucosidase liquid is obtained; and carrying out enzymatic reaction on soy isoflavone by using the purified beta-glucosidase liquid to obtain the soy isoflavone aglycone. The method has the advantages that the bean dreg culture medium is utilized for fermentation to produce beta-glucosidase, and the combined soy isoflavone is subjected to enzymolysis, so that the utilization of the byproduct bean dregs is improved, the biotransformation of isoflavone is realized, and the obtained product has better activity.

The invention provides a nanoparticle compound for inhibiting bone and soft tissue infection as well as a preparation method and application thereof, and belongs to the technical field of medical biological materials. The nanoparticle compound is a gentiopicroside, sericin, hyaluronic acid and endolysin liposome nanoparticle, and a gentiopicroside, sericin, hyaluronic acid and endolysin co-delivery nano drug delivery system targeting the S100A4 site is designed based on the target S100A4 closely related to bone infection through Ai molecular docking and nano drug delivery technologies. The nanoparticle compound provided by the invention has better stability and bioavailability, and can be used for improving and relieving inflammatory response and increasing wound healing effect.

The present invention relates to the field of biotechnology, and specifically discloses a β-glucosidase and its application in the preparation of ginsenosides. The β-glucosidase of the present invention or a recombinant microorganism expressing the enzyme can generate rare ginsenosides Rg3 and / or Rh1 through whole-cell catalysis, and then the application of the β-glucosidase of the present invention in the preparation of ginsenosides is proposed, and the amino acid sequence of the β-glucosidase is numbered RLF05189.1 on NCBI. The present invention provides a new method for synthesizing ginsenoside Rg3 and / or Rh1, preferably using a whole-cell catalytic method for production, and also has the advantages of short cycle, strong reaction specificity, high yield, low pollution, and simple process.